Clindamycin Dosing Recommendations
For adults with serious infections, clindamycin should be dosed at 600-900 mg IV every 8 hours, with the higher dose (900 mg) preferred for severe infections, particularly intra-abdominal infections; for pediatric patients, the recommended dose is 10-13 mg/kg IV every 8 hours for serious infections, with oral dosing at 8-20 mg/kg/day divided into 3-4 doses depending on severity.
Adult Dosing
Intravenous Administration
- Serious infections: 600-900 mg IV every 8 hours 1, 2
- Severe infections: 900 mg IV every 8 hours is superior, particularly for intra-abdominal infections where meta-analysis demonstrated significantly higher cure rates (90.5% vs 75.6%, p=0.03) compared to the 600 mg dose 3
- Necrotizing infections: 600-900 mg IV every 8 hours when used in combination therapy (e.g., with penicillin for streptococcal or clostridial infections) 1, 2
Oral Administration
- Serious infections: 150-300 mg every 6 hours 4
- More severe infections: 300-450 mg every 6 hours 4
- Must be taken with a full glass of water to avoid esophageal irritation 4
Critical Drug Interaction
When combined with rifampicin, clindamycin clearance increases 3-fold and oral bioavailability drops dramatically (from 56% to as low as 4% with rifampicin 900 mg q12h). In this scenario, oral clindamycin is ineffective and should never be used. Instead, administer at least 3600-4800 mg/day IV, preferably by continuous infusion 5.
Pediatric Dosing
Intravenous Administration
- Serious infections: 10-13 mg/kg/dose IV every 8 hours 1, 2
- Age-based optimization (based on pharmacokinetic modeling):
Oral Administration
- Serious infections: 8-16 mg/kg/day divided into 3-4 equal doses 4
- More severe infections: 16-20 mg/kg/day divided into 3-4 equal doses 4
- Musculoskeletal infections (including MRSA): 30 mg/kg/day has proven effective in MRSA-prevalent communities, with no significant difference in outcomes compared to 40 mg/kg/day, and lower rates of sequelae 7
- Osteomyelitis protocol: 50 mg/kg/day IV for ~3 weeks, followed by 30 mg/kg/day oral for an additional 6 weeks 8
Important Pediatric Considerations
- Dose based on total body weight regardless of obesity 4
- Capsules are not suitable for children unable to swallow them whole; use clindamycin palmitate oral solution instead 4
- Maturation of clindamycin clearance reaches 50% of adult values at approximately 44 weeks postmenstrual age 9
Special Clinical Scenarios
Necrotizing Soft Tissue Infections
For streptococcal necrotizing fasciitis, always combine clindamycin (600-900 mg IV every 8 hours) with penicillin (2-4 million units every 4-6 hours) 1, 2. Clindamycin provides critical toxin suppression that penicillin alone cannot achieve.
Animal/Human Bite Wounds
Clindamycin 300 mg PO three times daily or 600 mg IV every 6-8 hours provides good coverage against staphylococci, streptococci, and anaerobes, but misses Pasteurella multocida - a critical pathogen in animal bites. Consider alternative agents for this indication 1.
Duration of Therapy
- β-hemolytic streptococcal infections: Continue for at least 10 days 4
- Standard serious infections: Treatment duration should be guided by clinical response, not arbitrary time limits
Critical Safety Warnings
Clostridioides difficile-associated diarrhea (CDAD) is the most serious adverse effect. If significant diarrhea develops during therapy, discontinue clindamycin immediately 4. This risk is particularly elevated in elderly patients (>60 years) and may occur up to 2 months after the last dose 4.
Monitoring Requirements
- Periodic liver and kidney function tests during prolonged therapy 4
- Blood counts during extended treatment 4
- Monitor for neuromuscular blockade when used with neuromuscular blocking agents 4